Cost-effectiveness of myocardial perfusion imaging in the evaluation of patients with known or suspected coronary artery disease

Leslee J. Shaw, D. S. Berman, Donald D Miller

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Substantial evidence supports the clinical application of myocardial perfusion imaging (MPI) in patients with suspected or chronic coronary artery disease (CAD). Current recommendations encourage the use of MPI for prognostication and as a 'gatekeeper' to cardiac catheterization. Moreover, recent economic evidence indicates that MPI, as a result of improved diagnosis and risk estimation, provides substantial cost savings when compared with other competitive modalities for suspected and known CAD. Thus, on the basis of both clinical and cost considerations, MPI is increasingly viewed as a cost-effective, non-invasive test that can be used to optimize management in patients with CAD.

Original languageEnglish (US)
JournalEuropean Heart Journal, Supplement
Volume3
Issue numberF
DOIs
StatePublished - Aug 1 2001

Fingerprint

Myocardial Perfusion Imaging
Cost-Benefit Analysis
Coronary Artery Disease
Costs and Cost Analysis
Cost Savings
Cardiac Catheterization
Economics

Keywords

  • Cost-effectiveness
  • Economic evaluation
  • Myocardial perfusion imaging

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{1511804a2dcf4f0480409beb92b59fb4,
title = "Cost-effectiveness of myocardial perfusion imaging in the evaluation of patients with known or suspected coronary artery disease",
abstract = "Substantial evidence supports the clinical application of myocardial perfusion imaging (MPI) in patients with suspected or chronic coronary artery disease (CAD). Current recommendations encourage the use of MPI for prognostication and as a 'gatekeeper' to cardiac catheterization. Moreover, recent economic evidence indicates that MPI, as a result of improved diagnosis and risk estimation, provides substantial cost savings when compared with other competitive modalities for suspected and known CAD. Thus, on the basis of both clinical and cost considerations, MPI is increasingly viewed as a cost-effective, non-invasive test that can be used to optimize management in patients with CAD.",
keywords = "Cost-effectiveness, Economic evaluation, Myocardial perfusion imaging",
author = "Shaw, {Leslee J.} and Berman, {D. S.} and Miller, {Donald D}",
year = "2001",
month = "8",
day = "1",
doi = "10.1016/S1520-765X(02)90043-X",
language = "English (US)",
volume = "3",
journal = "European Heart Journal, Supplement",
issn = "1520-765X",
publisher = "Oxford University Press",
number = "F",

}

TY - JOUR

T1 - Cost-effectiveness of myocardial perfusion imaging in the evaluation of patients with known or suspected coronary artery disease

AU - Shaw, Leslee J.

AU - Berman, D. S.

AU - Miller, Donald D

PY - 2001/8/1

Y1 - 2001/8/1

N2 - Substantial evidence supports the clinical application of myocardial perfusion imaging (MPI) in patients with suspected or chronic coronary artery disease (CAD). Current recommendations encourage the use of MPI for prognostication and as a 'gatekeeper' to cardiac catheterization. Moreover, recent economic evidence indicates that MPI, as a result of improved diagnosis and risk estimation, provides substantial cost savings when compared with other competitive modalities for suspected and known CAD. Thus, on the basis of both clinical and cost considerations, MPI is increasingly viewed as a cost-effective, non-invasive test that can be used to optimize management in patients with CAD.

AB - Substantial evidence supports the clinical application of myocardial perfusion imaging (MPI) in patients with suspected or chronic coronary artery disease (CAD). Current recommendations encourage the use of MPI for prognostication and as a 'gatekeeper' to cardiac catheterization. Moreover, recent economic evidence indicates that MPI, as a result of improved diagnosis and risk estimation, provides substantial cost savings when compared with other competitive modalities for suspected and known CAD. Thus, on the basis of both clinical and cost considerations, MPI is increasingly viewed as a cost-effective, non-invasive test that can be used to optimize management in patients with CAD.

KW - Cost-effectiveness

KW - Economic evaluation

KW - Myocardial perfusion imaging

UR - http://www.scopus.com/inward/record.url?scp=0034916667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034916667&partnerID=8YFLogxK

U2 - 10.1016/S1520-765X(02)90043-X

DO - 10.1016/S1520-765X(02)90043-X

M3 - Article

AN - SCOPUS:0034916667

VL - 3

JO - European Heart Journal, Supplement

JF - European Heart Journal, Supplement

SN - 1520-765X

IS - F

ER -